Navigation Links
Researchers from Emory University Undertake A New Genetic Mapping

Researchers from Atlanta have announced that in a new project they've begun to draw out a new kind of genetic data that may help explain why some people// are susceptible or resistant to certain diseases.

It has been reported that the synopsis of the project that is being undertaken by the researchers of the Emory University was released yesterday, the 10th August, and it is to be published in the scientific journal, Genome Research. Lisa Brooks the director of the Institute's genetic variation program, of the National Human Genome Research Institute, a federal agency, said, “The topic is quite exciting" and the Emory researchers are breaking new ground.”

The research scientists are of the opinion that in around 10 years, doctors would be able to examine the DNA of newborn babies, and compare it to a reference code of human DNA so as to anticipate an infant's vulnerability to any disease. They explained that they hope that such information could help doctors in knowing as to which medicines would work most efficiently on any particular illness that could develop in a person.

Scott Devine, an Emory assistant professor of biochemistry and the co-author the paper said, “We're entering an exciting new era of predictive health,” he also added that the work by Emory should also contribute towards that. It was reported that in the year 2000 scientists had announced to finish considerably mapping the genetic blueprint for all human cells. The scientific community had heralded that breakthrough as ushering in a new era of medicine, which would, and to a certain extent has now, led to the findings of newer methods for treating and testing of the diseases.

In 2003, scientists had published the completed human genome sequence based on the DNA obtained from about a half-dozen people. It was reported that the mapping had showed that the human genome is made from billions of chemical building blocks that appear in pairs. They explain ed that these blocks come in four types: adenine (A), thymine (T), cystosine (C), and guanine (G).

The scientists have since then have been concentrating their attention for mapping the tiny variations in the genetic code of an additional 36 people, attempting to try and understand as to why certain people suffer from diseases, while others don’t, like for example why a non-smoker could develop lung cancer while some life long smokers do not get sick.

It was reported that a federally led mapping of the variations called "snips" _ or SNPs, an abbreviation for ‘single-nucleotide polymorphisms’ was published in 2005.

The scientists explained that those variations involve single-block replacements, meaning part of one person's genetic sequence might read A-T-C, but a SNP might replace a G for the C in the next person, resulting in A-T-G.

The Emory researchers explained that they used the SNP mapper’s data, but used a new kind of computer-based analysis to search for another type of variation known as ‘INDEL’ for insertion and deletion polymorphism. They explained that in an INDEL, the building blocks are added or deleted, but not just switched on a one-for-one basis, and that an insertion or deletion can involve thousands of blocks.

The Emory researchers said that the INDEL’s represent as much as 25 percent of all genetic variations. Devine said that they have already have been shown to be the cause of several genetic diseases, including cystic fibrosi.


'"/>




Related medicine news :

1. Researchers urge caution in using ear tube surgery
2. Researchers Scale to assess the Severity of Epilepsy in Kids
3. Researchers trick Alzheimers Enzyme
4. Researchers find new HIV hiding place
5. New Hair in 15 Days Could Now Be A Possibility Say Researchers
6. Researchers developed world’s smallest toothbrus
7. Researchers discover receptor cells that can cause epilepsy
8. 15 Anti-SARS Drugs Identified By China-Europe Team of Researchers
9. Researchers reversed the process of memory loss
10. Researchers Identify Key Gene That May Help Brain Treatment
11. Researchers Discover Protein That Causes Malaria
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/22/2017)... Peoria, IL (PRWEB) , ... May 22, 2017 ... ... HealthCare, is part of a larger group investing in InsightRX, an early stage ... a patient’s underlying biological and pharmacological characteristics. Greatpoint Ventures Innovation Fund ...
(Date:5/21/2017)... FL (PRWEB) , ... May 20, 2017 , ... Pot. ... it, find it, review it, and share its attributes like never before. More than ... directory to connect cannabis enthusiasts to stores, strains, products – and for the first ...
(Date:5/21/2017)... ... May 21, 2017 , ... ... longer than six months since you've seen a dentist, it's time for a ... and getting x-rays once per year. , Dental checkups are a relatively easy ...
(Date:5/19/2017)... ... May 19, 2017 , ... Springfield, Vermont-based law firm ... Titled " Ten Good Reasons To Hire An Experienced Personal Injury Attorney, " the ... an accident or injury. As the article says. if someone is injured due ...
(Date:5/19/2017)... ... 19, 2017 , ... As a groundbreaking surgeon on the frontline of prostate ... screenings. Early detection of the disease, he says, can make a world of difference. ... , stands alongside the Georgia Comprehensive Cancer Control’s (GC3) Prostate Cancer Task Force and ...
Breaking Medicine News(10 mins):
(Date:5/22/2017)...  As the specialty pharmacy industry and the ... the revolutionary shift from volume-based to value-based care, ... patient outcomes and shaping the future of the ... from clinical trials and toward data that reveals ... therapy utilization in precise patient populations. Therigy ® ...
(Date:5/18/2017)...  Bayer announced today that the latest research from ... the 53 rd Annual Meeting of the American ... in Chicago . ... liver and thyroid cancers, as well as lymphomas, and ... trial of copanlisib in patients with relapsed or refractory ...
(Date:5/15/2017)... 2017 Enterin Inc., a privately-held CNS pharmaceutical company ... compounds to treat Parkinson,s disease (PD), has enrolled the first ... 1/2a randomized, controlled, multicenter study involving patients with PD and ... patients over a 9-to-12-month period. The first stage is open ... PD. Participating sites include Denver , ...
Breaking Medicine Technology: